{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"name":"NCT05141721","nct_id":"NCT05141721","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct05141721. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"After receiving up to 24 weeks induction therapy with a fluoropyrimidine/oxaliplatin/bevacizumab (with or without irinotecan), per standard of care and after completing vaccine production screening, patients will receive a total of 6 administrations of GRT-C901/GRT-R902 plus ipilimumab co-administered only with the first dose of GRT-C901 and GRT-R902. All patients will receive atezolizumab in addition to maintenance therapy of a fluoropyrimidine and bevacizumab according to standard of care.","label":"Vaccine Arm","type":"EXPERIMENTAL"},{"description":"After receiving up to 24 weeks induction therapy with a fluoropyrimidine/oxaliplatin/bevacizumab (with or without irinotecan), per standard of care and undergoing vaccine production screening, patients will receive maintenance therapy of a fluoropyrimidine and bevacizumab according to standard of care.","label":"Control Arm","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2027-03","type":"ESTIMATED"},"conditions":["Colorectal Neoplasms"],"enrollment":{"count":700,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"GRT-C901","otherNames":[],"type":"DRUG"},{"name":"GRT-R902","otherNames":[],"type":"DRUG"},{"name":"Atezolizumab","otherNames":["Tecentriq"],"type":"DRUG"},{"name":"Ipilimumab","otherNames":["Yervoy"],"type":"DRUG"},{"name":"Fluoropyrimidine plus leucovorin","otherNames":["Xeloda"],"type":"DRUG"},{"name":"Bevacizumab","otherNames":["Avastin"],"type":"DRUG"}],"last_update":"2025-05-16","lead_sponsor":"Seattle Project Corporation","official_title":"A Phase 2/3, Randomized, Open-Label Study of Maintenance GRT-C901/GRT-R902, A Neoantigen Vaccine, in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2","PHASE3"],"primary_completion_date":{"date":"2027-03","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Phase 2: Molecular response defined as ≥ 30% decrease from baseline in circulating tumor DNA (ctDNA)","timeFrame":"Baseline and up to 27 months"},{"measure":"Phase 3: Progression-free survival per Immune-based Response Evaluation Criteria in Solid Tumors (iRECIST) as assessed by blinded independent review committee (IRC)","timeFrame":"Up to 60 months"}],"references":[],"start_date":{"date":"2022-02-12","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer","url":"https://clinicaltrials.gov/study/NCT05141721"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct05141721"}